Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 MDNAF | Healthcare | $0.27 | 32.96K | $21.21M | -1.75 | ― | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MDNAF | Medicenna Therapeutics Corp | 0.27 | -0.74 | -73.12% |
| Name | Price | % Change | |
|---|---|---|---|
| MDNAF | $0.27 | -73.12% |
Medicenna Therapeutics (MDNA) is scheduled to report 2nd quarter earnings on 11/12/2026. Regarding Q2 estimates, Wall Street analysts expect Medicenna Therapeutics to post earnings of -C$0.05 per share. Last quarter,
An update from Medicenna Therapeutics Corp ( ($TSE:MDNA) ) is now available. Medicenna Therapeutics reported new preclinical data on MDNA209, its engineered CD122 superantagonist, showing tight binding to CD122 and
An announcement from Medicenna Therapeutics Corp ( ($TSE:MDNA) ) is now available. Medicenna Therapeutics will present new preclinical data on MDNA209, a long-acting CD122 superantagonist engineered to block IL-2 and
Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an announcement. Medicenna shareholders elected all management-nominated directors with more than 97% support and approved the re-appointment of MNP LLP as auditor
Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has issued an announcement. Medicenna Therapeutics said new survival data for its lead candidate bizaxofusp in unresectable, IDH-wildtype recurrent glioblastoma has been selected for
Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an update. Medicenna Therapeutics Corp., listed on the TSX and OTCQX, operates as a clinical-stage immunotherapy innovator focused on engineered cytokine therapies
An update from Medicenna Therapeutics Corp ( ($TSE:MDNA) ) is now available. Medicenna reported fiscal 2027 first-quarter results and said cash and cash equivalents stood at $5.7 million at June
Medicenna Therapeutics (MDNA) is scheduled to report 4th quarter earnings on 06/25/2026. Regarding Q4 estimates, Wall Street analysts expect Medicenna Therapeutics to post earnings of -C$0.06 per share. Last quarter,
Medicenna Therapeutics (MDNAF) presented new positive preclinical data from MDNA113, its first-in-class tumor-anchored and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine, at the American Association for Cancer Research Annual Meeting
Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an announcement. Medicenna Therapeutics will showcase its latest corporate developments and preclinical data on its MDNA113 bifunctional immunotherapy candidate at the 2026
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| MDNAF | Feb 11, 2027TBA | $21.21M | ― | ― | -0.06 | -1.75 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
